NUVISAN The Science CRO
Norman Liaw is the Head of iPSC Platform at NUVISAN The Science CRO, leading a team in establishing a disease modeling and drug screening platform using induced pluripotent stem cells. Norman is also involved in future strategy, legal, and business development aspects in the field. Norman is an Honorary Research Fellow at the University of Melbourne in the Department of Paediatrics and at the Murdoch Childrens Research Institute. Norman previously worked as a Postdoctoral Scientist in cardiovascular research at DZHK Deutsches Zentrum für Herz-Kreislauf-Forschung e. V. and Universitätsmedizin Göttingen. Norman holds a PhD from the University of Melbourne and a Bachelor of Science (Hons.) in Biomedical Sciences from Monash University.
This person is not in the org chart
NUVISAN The Science CRO
1 followers
Founded in Europe with more than 40 years of experience, NUVISAN is a fully integrated contract research and development, and manufacturing organization (CRO/CDMO) that offers unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain. With more than 1.000 employees distributed over six locations in Germany and France including our drug discovery hub in Berlin as well as with local experts situated in Latin America, NUVISAN is pleased to offer the following portfolio of services: • Drug discovery & research - Discovery pharmacology - Discovery bioscience - Screening - Life science chemistry - Translation research - Digital life science - Toxicology - DMPK • Non-clinical studies • Pharmaceutical analysis • Topical formulation development • Chemical development with GMP manufacturing (3-10kg) • Bioanalytical labs • GMP manufacturing (up to 50Kg) • Clinical trial supplies • Phase 1 and 2 clinical studies and beyond Our services can be provided as stand-alone or integrated solutions and can be customized to your project. Email us at hello@nuvisan.com for more.